The Lancet20m
Sodium–glucose co-transporter inhibitors—who would have guessed?
Prediction is very difficult, especially about the future”; whether it is the Nobel laureate Niels Bohr or others who have ...
Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...